Teva Pharmaceutical Industries Limited (TEVJF)
OTCMKTS · Delayed Price · Currency is USD
17.80
-1.51 (-7.82%)
At close: May 28, 2025

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202017 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Generics, Innovative Medicines and Biopharmaceuticals
61.24B
Log In
Log In
Log In
Log In
Upgrade
Generics, Innovative Medicines and Biopharmaceuticals Growth
4.79%
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202017 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
United States
29.74B
Log In
Log In
Log In
Log In
Upgrade
United States Growth
-0.74%
Log In
Log In
Log In
Log In
Upgrade
Europe
18.89B
Log In
Log In
Log In
Log In
Upgrade
Europe Growth
5.89%
Log In
Log In
Log In
Log In
Upgrade
International
9.12B
Log In
Log In
Log In
Log In
Upgrade
International Growth
26.26%
Log In
Log In
Log In
Log In
Upgrade
Global
3.49B
Log In
Log In
Log In
Log In
Upgrade
Global Growth
2.32%
Log In
Log In
Log In
Log In
Upgrade